Addrenex makes appointments
This article was originally published in Scrip
Executive Summary
Addrenex Pharmaceuticals, a two-year-old US firm, has appointed Steven Butts vice-president of commercial affairs, Dr Gary Bream senior director of scientific affairs, and Yuki Prescott clinical trials manager. Mr Butts has worked at Biobehavioral Diagnostics and Lilly, while Dr Bream and Ms Prescott most recently served at Constella. Addrenex has filed a sustained-release clonidine product, CloniBID, for US approval in hypertension, and has an extended-release clonidine, Clonicel, in Phase III trials for attention deficit hyperactivity disorder; both products will be marketed by licensee Sciele Pharma.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.